Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Granules India Limited ( (IN:GRANULES) ) has provided an announcement.
Granules India Limited announced that its wholly owned U.S. subsidiary, Granules Pharmaceuticals, Inc. in Chantilly, Virginia, has successfully completed a routine current Good Manufacturing Practices audit conducted by the U.S. Food and Drug Administration. The inspection, held from March 30 to April 3, 2026, resulted in four Form 483 observations that were described as procedural in nature.
The company emphasized that there were no data integrity related findings during this second FDA inspection of the Chantilly facility within the last year. Granules stated it remains committed to high standards of quality, safety, and regulatory compliance and plans to address the noted procedural observations within the timelines specified by the regulator.
More about Granules India Limited
Granules India Limited is an India-based pharmaceutical company that operates through subsidiaries such as Granules Pharmaceuticals, Inc. in Chantilly, Virginia, U.S. The group focuses on producing and supplying pharmaceutical products to regulated markets, requiring adherence to stringent quality and regulatory standards set by agencies like the U.S. Food and Drug Administration.
Average Trading Volume: 51,967
Technical Sentiment Signal: Buy
Current Market Cap: 149B INR
See more insights into GRANULES stock on TipRanks’ Stock Analysis page.